UK markets close in 3 hours 54 minutes

Biotest Aktiengesellschaft (0N6Z.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
20.40+0.90 (+4.62%)
As of 4:15PM BST. Market open.
Full screen
Previous close19.50
Open20.40
Bid0.00 x N/A
Ask0.00 x N/A
Day's range20.40 - 20.40
52-week range20.40 - 20.40
Volume330,662
Avg. volumeN/A
Market cap734.686M
Beta (5Y monthly)0.71
PE ratio (TTM)N/A
EPS (TTM)-0.80
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Biotest AG: Biotest supports clinical study with Pentaglobin(R) in COVID-19 at the University Hospital AKH Vienna

    DGAP-News: Biotest AG / Key word(s): Study23.02.2021 / 07:00 The issuer is solely responsible for the content of this announcement.PRESS RELEASEBiotest supports clinical study with Pentaglobin(R) in COVID-19 at the University Hospital AKH Vienna University Hospital AKH Vienna investigates various COVID-19 therapies in platform trial (ACOVACT) Additional study arm with Pentaglobin(R) started Pentaglobin(R) supports the immune system in eliminating bacteria and toxins and can regulate excessive immune responses Dreieich, 23 February 2021. In a study arm of the ACOVACT trial, the treatment of patients with severe COVID-19 with Pentaglobin(R) has been started. ACOVACT (Austrian CoronaVirus Adaptive Clinical Trial) is a multicentre, randomised, controlled, open-label platform trial initiated by the University Hospital AKH Vienna to study various antiviral and adjunctive therapies for COVID-19 patients.In the study arm, investigating immunomodulatory therapies, 20 COVID-19 patients in intensive care with pneumonia and elevated inflammatory markers and with a risk of developing sepsis or acute respiratory failure will be treated with Pentaglobin(R)."Due to its immunomodulating effect, we believe Pentaglobin(R) offers a promising approach for treating severe courses of COVID-19 disease and we aim to investigate this more in detail in the ACOVACT trial," emphasises Univ.-Prof. Dr. Roman Ullrich, Senior Consultant Intensive Care Medicine at the University Clinic for Anaesthesia at the Medical University Vienna who is the principal investigator of the sub-study with Pentaglobin(R).The IgM-enriched immunoglobulin preparation Pentaglobin(R) is an established treatment option for patients with severe bacterial infections. A meta-analysis of patients with sepsis and septic shock demonstrated a significant reduction in mortality and a shorter duration of mechanical ventilation.[1] Pentaglobin(R) has an immunomodulatory effect and could therefore help to positively influence the often excessive immune response in severe courses of COVID-19. In addition, the antibodies in Pentaglobin(R) can bind to a variety of bacteria and their toxins, supporting their destruction by the immune system. Secondary bacterial infections are increasingly being observed in COVID-19 patients with severe courses of the disease. Biotest supports the project within the scope of an academic-industry collaboration (Investigator Initiated Study).About Pentaglobin(R)Pentaglobin(R) is the first and only IgM-enriched immunoglobulin preparation for intravenous use. Pentaglobin(R) significantly increases the survival rate of patients with severe bacterial infections and acts against a broad spectrum of bacterial pathogens. Pentaglobin(R) acts anti-bacterial by neutralization of bacterial endo- and exotoxins and anti-inflammatory by scavenging excessively activated complement factors. Pentaglobin(R) is licensed in several countries for the treatment of severe bacterial infections in combination with antibiotics.About COVID-19COVID-19 is a respiratory disease caused by the novel severe acute respiratory syndrome corona virus 2 variant (SARS-CoV-2). While most cases are mild or asymptomatic, COVID-19 patients may present at the hospital with typical signs of pneumonia requiring oxygen support. This disease stage is regularly accompanied by an excessive immune response and can lead to systemic inflammation reactions. Furthermore, patients may progress to critical disease with need for intensive care, including invasive mechanical ventilation. This clinical picture and course of the disease resembles that of severe community acquired pneumonia (sCAP) caused by other pathogens.About BiotestBiotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.IR contactDr Monika ButtkereitPhone: +49-6103-801-4406Mail: investor_relations@biotest.dePR contactDirk NeumüllerPhone: +49-6103-801-269Mail: pr@biotest.comBiotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.comOrdinary shares: securities' ID No. 522720; ISIN DE0005227201Preference shares: securities' ID No. 522723; ISIN DE0005227235Listing: Frankfurt (Prime Standard)Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, TradegateDisclaimerThis document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.[1] Cui et al. Ann. Intensive Care 9, 27 (2019). https://doi.org/10.1186/s13613-019-0501-323.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Biotest AG Landsteinerstraße 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1170123 End of News DGAP News Service

  • EQS Group

    Biotest AG: Biotest is the first plasma protein manufacturer in Germany to produce an investigational hyperimmunoglobulin preparation against COVID-19 and can provide further production capacities

    DGAP-News: Biotest AG / Key word(s): Research Update18.02.2021 / 07:00 The issuer is solely responsible for the content of this announcement.PRESS RELEASEBiotest is the first plasma protein manufacturer in Germany to produce an investigational hyperimmunoglobulin preparation against COVID-19 and can provide further production capacities if the treatment is proven safe and effective and authorized for use Biotest is participating in cross-industry development of an investigational therapy for the treatment of COVID-19 Important milestone achieved in potential hyperimmune therapy against COVID-19 COVID Convalescent Plasma (CCP) donations collected by the CoVIg-19 Plasma Alliance have been successfully processed to manufacture a potential hyperimmunoglobulin therapy against COVID-19 using production technology from BiotestDreieich, 18 February 2021. As part of the CoVIg-19 Plasma Alliance, Biotest is working intensively on a potential medicine against COVID-19 using CCP donated by recovered patients. The goal of the CoVIg-19 Plasma Alliance is to jointly develop a potential hyperimmunoglobulin against COVID-19 that each member can produce at their manufacturing facilities and subsequently make available following authorization. Plasma donations collected by members of the Alliance are pooled, concentrated and purified to make a medicine with high levels of antibodies to SARS-CoV-2, if proven safe and effective in a clinical trial, which has just completed enrolment. Biotest has many decades of experience as a specialist in manufacturing hyperimmunoglobulins from blood plasma. This technology has now also been used to manufacture a potential hyperimmunoglobulin preparation against COVID-19.As part of the CoVIg-19 Plasma Alliance, Biotest has now achieved an important milestone. At the Dreieich site in Germany, the first batch of a hyperimmunoglobulin with a high content of neutralising antibodies against COVID-19 has been successfully produced at scale. The plasma donations as the raw material for production were collected in Europe and in the US by the CoVIg-19 Plasma Alliance partners. Biotest, and other members, can provide further production capacities if the product is authorized and there remains patient need at that time.The first hyperimmunoglobulin preparations from the CoVIg-19 Plasma Alliance are already undergoing clinical trials coordinated by the US National Institutes of Health (NIH). Patient enrolment in the trial has now completed. On the basis of this cross-company clinical development, Biotest is aiming to obtain approval for its hyperimmunoglobulin, which is based on Biotest's established hyperimmunoglobulin technology.About the CoVIg-19 Plasma AllianceThe CoVIg-19 Plasma Alliance is an unprecedented partnership of the world's leading plasma companies, spanning plasma collection, development, production and distribution. Rather than pursue our individual research, we are putting public and patient health first by working together. Our goals are to accelerate the development of a potential treatment, improve our chances of success and increase supply of the potential treatment.Other Alliance members who have manufactured the H-Ig that we all refer to as CoVIg-19 include CSL Behring and Takeda.The Alliance includes Biotest, CSL Behring, LFB, Octapharma, Sanquin, Takeda, BioPharma Plasma, GC Pharma and NBI. The Bill & Melinda Gates Foundation is providing advisory support. Microsoft is providing technology including the Alliance website and the Plasma Bot for donor recruitment.About human blood plasmaHuman blood plasma is a raw material used to produce plasma derived products, which are used to treat various illnesses of the immune system, the blood system, as well as in emergency medicine. Biotest is one of the world's six largest manufacturers of plasma protein medicines.About BiotestBiotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.IR contactDr Monika ButtkereitPhone: +49-6103-801-4406Mail: investor_relations@biotest.dePR contactDirk NeumüllerPhone: +49-6103-801-269Mail: pr@biotest.comBiotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.comOrdinary shares: securities' ID No. 522720; ISIN DE0005227201Preference shares: securities' ID No. 522723; ISIN DE0005227235Listing: Frankfurt (Prime Standard)Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, TradegateDisclaimerThis document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.18.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Biotest AG Landsteinerstraße 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1169114 End of News DGAP News Service

  • EQS Group

    Biotest AG: Biotest significantly exceeds Revenue and EBIT guidance

    Biotest AG / Key word(s): Preliminary ResultsBiotest AG: Biotest significantly exceeds Revenue and EBIT guidance11-Feb-2021 / 17:54 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Ad-hoc RELEASEAnnouncement according to Article 17 European Market Abuse Regulation (MAR)Biotest significantly exceeds Revenue and EBIT guidanceDreieich, 11 February 2021. According to preliminary and not yet audited figures, Biotest AG increased its revenues by more than 15% to € 484 million in fiscal year 2020, compared to € 419 million in the previous year. The increase in revenues primarily resulted from higher sales in the regions Middle East and Africa and Rest of Europe. Among other things, the entry into the Chinese market had a positive impact.Although the year-end closing work is still ongoing, it is becoming apparent that the operating result (earnings before interest and taxes, EBIT) in fiscal 2020 will be between € - 1 to - 2 million. In 2019, EBIT amounted to € - 1.2 million.Thus Biotest Group concluded 2020 with a significantly better result than what has been published as EBIT guidance of € - 10 million for 2020. The improvement is mainly attributable to higher sales, lower administrative expenses and one-time other operating income in the fourth quarter.In the 2020 financial year, EBIT continued to be impacted by higher expenses in connection with the start-up phase of the new Biotest Next Level production facility. In addition, higher research and development expenses for the new products, which will be manufactured exclusively in the Biotest Next Level facility, as well as two additionally, initiated development projects for a therapy against a COVID-19 infection negatively influenced the result.Biotest will publish final results for the Financial Year 2020 and the annual report on March 31, 2021. The virtual Annual General Meeting of Biotest AG without physical presence will take place on May 11, 2021.Biotest AktiengesellschaftBoard of ManagementBiotest AGLandsteinerstr. 5D-63303 Dreieichwww.biotest.comDisclaimerThis document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.About BiotestBiotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 1,900 employees worldwide. The preference shares of Biotest AG are listed in the Prime Standard on the Frankfurt stock exchange.IR contactDr. Monika Buttkereitphone: +49-6103-801-4406email: investor_relations@biotest.dePR contactDirk Neumüllerphone: +49-6103-801-269email: pr@biotest.comBiotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.comOrdinary shares: securities' ID No. 522720; ISIN DE0005227201Preference shares: securities' ID No. 522723; ISIN DE0005227235Listing: Frankfurt (Prime Standard)Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, TradegateContact:Dr. Michael RamrothChief Financial OfficerBiotest AGLandsteinerstr. 363303 DreieichTel. +40 6103 801 338Fax: +49 6103 801 347Michael.ramroth@biotest.com11-Feb-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: Biotest AG Landsteinerstraße 5 63303 Dreieich Germany Phone: 0 61 03 - 8 01-0 Fax: 0 61 03 - 8 01-150 E-mail: investor_relations@biotest.de Internet: http://www.biotest.de ISIN: DE0005227235, DE0005227201 WKN: 522723, 522720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1167844 End of Announcement DGAP News Service